## Introduction

Genital warts (condyloma acuminatum, venereal warts) are common highly contagious benign epithelial lesions occurring on the genitals, perianal area, and inguinal folds, and are caused by human papillomavirus (HPV) (*Brodell et al., 2007*).

Warts are not exclusive to external genital tissues. Sexual exposure can be associated with warts in the urethra and at the meatus, cervix, vagina, anus, and oral cavity (Wiley et al., 2002).

More than 100 HPV types have been described, with approximately a third of these types predominantly infecting the genital epithelium. Approximately 90% of GWs are caused by HPV 6 or 11, and up to 70% of cervical cancers are caused by HPV 16 or 18, and HPV 6, 11, 16, 18 cause one-third of low-grade cervical lesions. Therefore, only 4 HPV types are responsible for the majority of the burden of HPV disease (Munoz et al., 2003).

In the United States, Genital HPV is the most common sexually transmitted infection, with an estimated 80% lifetime risk of acquiring HPV at least once (Baseman & Koutsky ,2005).

The incidence of GWs has steadily increased since the early 1970s in every country where such data have been evaluated. In the United States, the incidence of GWs increased from 13/100,000 in the years 1950-54 to 106/100,000 in the years 1975-78, and clinicians reported a 450% increase in the treatment of GWs from 1966 to 1984 (Baseman & Koutsky, 2005).

In a study on the prevalence of HPV infection among a highrisk group of Egyptian women, PCR in-situ hybridization of cervical biopsies revealed an approximately 70% infection rate (*Abdel Aziz et al.*, 1998), but no data are available on the infection rate in the general population (*Abdel Aziz et al.*, 2006).

The majority of genital warts are described as "cauliflower-like" condyloma acuminata, or genital papillomas. GWs can also be domeshaped, papular, pedunculated, or flat, and they can occur as single lesions, in clusters, or as plaques (*Habif*, 2004).

HPV infection, unlike many genitourinary infections, is not usually associated with immediate symptoms such as itching , burning ,and vaginal discharge . Rather , the majority of those infected with HPV will not develop clinical disease or symptoms because the host immune system resolves most infections. In one study, only 24.8% of women infected with HPV 6 or 11 actually developed GWs. (Mao et al., 2003)

The greatest risk factors for infection are gender, age, and sexual activity, with the highest rates being consistently found in sexually active women less than 25 years of age ( *Winer et al.*,2003).

Histologically, a wart demonstrates acanthotic epidermis with papillomatosis, hyperkeratosis and parakeratosis. Koilocytes are often observed, and the rete ridges often form thick bands extending extensively into the underlying, highly vascular dermis (*Lowry & Androphy*, 2003).

Not only are GWs unsightly, but their persistence and inconstant response to treatment cause anxiety and introspection in the patient and give the patient the burden of multiple clinic attendances. (McMillan & Ogilvie, 2004)

There are multiple treatments for GWs, but none that directly eradicate HPV. Of these, the Centers for Disease Control and Prevention Sexually Transmitted Disease Guidelines recommend BCA (bichloroacetic acid), TCA( trichloroacetic acid), cryotherapy podophyllin resin and surgical removal as first-line provider-applied therapies, and podofilox, imiguimod and sinecatechins as first-line therapies (CDC Sexually Transmitted Disease patient-applied Guidelines., 2010).

Primary prevention approaches for GWs have been limited in the past to abstinence, mutual long-term fidelity, or use of condoms. Until recently, the first 2 options were believed to be the only effective approaches because condom use has now been shown to reduce the risk of acquiring HPV by 70% only in a population of young women (Winer et al., 2003).

The most effective tool for primary prevention is undoubtedly vaccination with an quadrivalent HPV vaccine containing HPV types 6, 11, 16, and 18. The potential for prevention of over 90% of all genital HPV lesions in young girls and women not previously exposed will be the most immediate vaccination benefit, while prevention of 70% of cervical cancers is the most dramatic and lifesaving benefit of this vaccine (*Frazer et al.*, 2006).